ArticleScientific reports2026
Functional characterization of angiogenesis genes in hepatocellular carcinoma via integrated bulk and single cell RNA sequencing.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) originates from hepatocytes and accounts for over 80% of primary liver cancers. Despite numerous studies have explained the role of certain angiogenesis-related and integrated stress response related genes in the development of HCC, few studies have explored the function of all angiogenesis-related and ISR(Integrated stress response)-related genes, as well as their applications in therapeutic prediction models. Here, by integrating bulk and single cell transcriptome data, We first explored the expression patterns of genes at the intersection of angiogenesis and the integrated stress response (ISR). To comprehensively identify angiogenesis-related gene modules, we then performed WGCNA (weighted gene co-expression network analysis) using a broader angiogenesis gene set, revealing modules strongly correlated with angiogenic activity.Based on these core genes, we constructed a prognostic model to evaluate patient outcomes and responses to immunotherapy, which is valuable for informing treatment options. Furthermore, through drug response modeling, we identified several drugs targeting angiogenesis genes that could serve as potential therapeutic options. Single-cell transcriptome analysis also revealed that DAB2, which is highly expressed in APOA2+ macrophages, may be involved in the cellular response to signals from fibroblast cells via the THY1 pathway. Finally, molecular docking studies indicated that dihydroergotamine might be a promising candidate drug for targeting DAB2. This study systematically investigated the expression changes of angiogenesis genes in HCC, constructed a tumor prognosis prediction model, and explored potential therapeutic targets and drugs. These findings are of significance for guiding the selection of treatment options and identifying therapeutic targets for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.